OXYGENTA PHARMACEUTICAL LIMITE
Latest filings
- Board to consider September 2026 quarterly and half-year results · Results
- Routine SEBI dematerialisation compliance certificate for Sep 2026 quarter · Compliance
- Oxygenta buys 36,421 sq mtr Telangana plot for about 6.75 crore · Strategic Transactions
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical products from a base in Telangana (manufacturing licence no. 10/MD/AP/2013/B/G). It is a subsidiary of Virupaksha Organics Limited, which acquired a 56.5% stake in June 2025 and continues open-market buying; the board is seeking shareholder approval for related-party sales and purchases with Virupaksha Organics of up to Rs 250 crore and for loans and guarantees of up to Rs 200 crore in FY 2026-27. The product mix is not disclosed in the filings, but the cost shape — 97.7% materials as a share of FY26 revenue — points to a formulation or trading-led model with limited value-added processing. Revenue was Rs 11,298.19 lakhs in FY26 (up 3.4% YoY) but the company posted a net loss of Rs 1,757.17 lakhs, with finance costs rising sharply (nearly 4x to Rs 245.50 lakhs in Q1 FY27). Q1 FY27 revenue surged 144% YoY to Rs 3,699.69 lakhs while the net loss narrowed to Rs 210.37 lakhs. Borrowings climbed to Rs 10,956.68 lakhs by year-end FY26 (from Rs 6,193.24 lakhs) and the ECLGS scheme was drawn for Rs 399 lakhs; equity has turned negative at Rs -4,268.68 lakhs.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from OXYGENTA PHARMACEUTICAL LIMITE's filed financials and exchange disclosures
What does OXYGENTA PHARMACEUTICAL LIMITE do?
OXYGENTA PHARMACEUTICAL LIMITE is a Pharmaceuticals & Biotechnology company listed on BSE.
Is OXYGENTA PHARMACEUTICAL LIMITE profitable?
No. Over the trailing twelve months OXYGENTA PHARMACEUTICAL LIMITE reported a net loss of ₹14 Cr on revenue of ₹135 Cr.
Does OXYGENTA PHARMACEUTICAL LIMITE pay a dividend?
Not in the latest reported year — OXYGENTA PHARMACEUTICAL LIMITE's dividend payout for FY26 was nil.
Is OXYGENTA PHARMACEUTICAL LIMITE debt-free?
No. It reported borrowings of ₹110 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹109 Cr after cash. Its net worth is negative — liabilities exceed assets by ₹43 Cr, so a debt-to-equity ratio is not meaningful.
How much does the OXYGENTA PHARMACEUTICAL LIMITE share price move in a day?
On a typical session OXYGENTA PHARMACEUTICAL LIMITE moves 1.96% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track OXYGENTA PHARMACEUTICAL LIMITE's announcements?
Every NSE and BSE filing by OXYGENTA PHARMACEUTICAL LIMITE appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.